EnteroBiotix to present results from IMPuLCE phase 1b trial of EBX─102 in patients with liver cirrhosis at EASL Congress ...
EnteroBiotix Limited (EnteroBiotix), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, announced that results from its IMPuLCE phase 1b trial evaluating EBX-102, the company’s next-generation full- …